Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101

Author:

Caramanna Ivan1ORCID,de Kort Julie M1,Brandes Alba A2ORCID,Taal Walter3ORCID,Platten Michael45,Idbaih Ahmed6ORCID,Frenel Jean Sebastien7,Wick Wolfgang58ORCID,Preetha Chandrakanth Jayachandran9,Bendszus Martin9,Vollmuth Philipp9,Reijneveld Jaap C1011,Klein Martin1

Affiliation:

1. Department of Medical Psychology, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands

2. Department of Medical Oncology, AUSL , Bologna , Italia

3. Department of Neurology , Erasmus MC Cancer Institute, Rotterdam , the Netherlands

4. Department of Neurology, Medical Faculty Mannheim , Mannheim , Germany

5. German Cancer Research Center , Heidelberg , Germany

6. Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013 , Paris , France

7. Department of Medical Oncology, Institut de Cancerologie de l’Ouest–Centre Rene Gauducheau , Saint-Herblain , France

8. Department of Neurology, University Hospital Heidelberg , Heidelberg , Germany

9. Department of Neuroradiology, Heidelberg University Hospital , Heidelberg , Germany

10. Department of Neurology, Stichting Epilepsie Instellingen Nederland (SEIN) , Heemstede , the Netherlands

11. Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands

Abstract

Abstract Background In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to corticosteroid treatment. Methods Using baseline data (ie, prior to randomization) of European Organization for Research and Treatment of Cancer (EORTC) trial 26101, we performed regression analysis to assess the predictive value of corticosteroid intake on performance of the EORTC brain tumor clinical trial NCF test battery. The battery is comprised of the Hopkins Verbal Learning Test—Revised (HVLT-R), Controlled Oral Word Association Test (COWA), and Trail Making Test (A and B). Results Out of 321 patients, 148 (46.1%) were not using corticosteroids, and 173 were using dexamethasone (34.3%), methylprednisolone (9.7%), or other corticosteroids (9.9%). Patients on corticosteroids had worse performance on all neurocognitive tests. Regression analyses demonstrated a negative association between corticosteroids use and the HVLT-R free recall score (R2 change = 0.034, F change (1, 272) = 13.392, P < .001) and HVLT-R Delayed Recall score (R2 change = 0.028, F change (1, 270) = 10.623, P = .002). No statistically significant association was found for HVLT-R Delayed recognition, COWA, TMT part A and TMT part B (P > .05). Conclusions Glioblastoma patients prescribed with corticosteroids show poorer memory functions, expressive language, visual-motor scanning speed, and executive functioning than patients not using corticosteroids. Furthermore, we found a negative association between corticosteroid intake and memory functions. The possibility of deleterious effects of corticosteroids on NCF should be considered during clinical decision making.

Funder

European Organisation for Research

Treatment of Cancer

Quality of Life Group

Publisher

Oxford University Press (OUP)

Subject

Medicine (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3